| scholarly article | Q13442814 |
| P356 | DOI | 10.1378/CHEST.99.4.1025 |
| P8608 | Fatcat ID | release_5j2il6gwqrhm7fpfcyuun2ikmq |
| P698 | PubMed publication ID | 1901260 |
| P2093 | author name string | J Berger | |
| M Saxena | |||
| J P Nadler | |||
| J A Nord | |||
| R Cofsky | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| P304 | page(s) | 1025-6 | |
| P577 | publication date | 1991-04-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis | |
| P478 | volume | 99 |
| Q21131083 | A new strategy to fight antimicrobial resistance: the revival of old antibiotics |
| Q40596683 | A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993. |
| Q38061197 | Advances In Mycobacterium Tuberculosis Therapeutics Discovery Utlizing Structural Biology. |
| Q64058473 | Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs |
| Q28377570 | Bactericidal action of ampicillin/sulbactam against intracellular mycobacteria |
| Q39782912 | Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. |
| Q37783433 | Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis |
| Q42984564 | Biochemical characterization of the 49 kDa penicillin-binding protein of Mycobacterium smegmatis |
| Q36675532 | Clinical effects of gemifloxacin on the delay of tuberculosis treatment |
| Q28486458 | Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra |
| Q28379554 | Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates |
| Q40397058 | Current and potential treatment of tuberculosis |
| Q35705874 | Current development and future prospects in chemotherapy of tuberculosis |
| Q33953505 | Drug treatment for tuberculosis during pregnancy: safety considerations |
| Q36924283 | Drug-Resistant Tuberculosis: Challenges and Progress |
| Q89208617 | Have we realized the full potential of β-lactams for treating drug-resistant TB? |
| Q24531943 | Imipenem for treatment of tuberculosis in mice and humans |
| Q36438910 | In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates |
| Q42109610 | In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors |
| Q36171768 | Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins |
| Q41329958 | Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate |
| Q36895711 | Key issues in multidrug-resistant tuberculosis |
| Q38040155 | Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. |
| Q40675039 | Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis |
| Q77831918 | Multidrug-resistant tuberculosis |
| Q41717742 | Multiple drug-resistant tuberculosis. |
| Q37720675 | Network and matrix analysis of the respiratory disease interactome |
| Q26751463 | New agents for the treatment of drug-resistant Mycobacterium tuberculosis |
| Q85268364 | Oldie but goodie: Repurposing penicillin for tuberculosis |
| Q28487218 | Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis |
| Q30322975 | Pharmacokinetic factors in the modern drug treatment of tuberculosis. |
| Q57158690 | Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future |
| Q35666918 | Programmes and principles in treatment of multidrug-resistant tuberculosis |
| Q38056147 | Reappraising the use of β-lactams to treat tuberculosis |
| Q92707789 | Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach |
| Q28367441 | Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents |
| Q42110234 | Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate |
| Q33778121 | The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. |
| Q40408985 | The treatment of tuberculosis: current status and future prospects |
| Q33768742 | Treatment and prevention of multidrug-resistant tuberculosis |
| Q39967041 | Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects |
| Q37340569 | Treatment of tuberculosis in children |
| Q64233651 | Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening |
| Q35365963 | Tuberculosis in the AIDS era |
| Q27660125 | Unusual Conformation of the SxN Motif in the Crystal Structure of Penicillin-Binding Protein A from Mycobacterium tuberculosis |
| Q33928681 | Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations |
| Q26852253 | WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis |
| Q35849799 | Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? |
| Q73150465 | [Multidrug resistant pulmonary tuberculosis in a pre-school infant] |
Search more.